



Beaver, K. M., Williamson, S., Sutton, C., Hollingworth, W., Gardner, A., Allton, B., ... Martin-Hirsch, P. (2017). Comparing hospital and telephone follow-up for patients treated for stage-I endometrial cancer (ENDCAT trial): A randomised, multicentre, non-inferiority trial. *BJOG: An International Journal of Obstetrics and Gynaecology*, 124(1), 150-160. DOI: 10.1111/1471-0528.14000

Link to published version (if available):
[10.1111/1471-0528.14000](https://doi.org/10.1111/1471-0528.14000)

[Link to publication record in Explore Bristol Research](#)
PDF-document

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/pure/about/ebr-terms.html>

Table 3. Information needs at follow-up by randomised group. * P-values from Fisher's exact test reported due to low cell frequencies.

	TFU		HFU		P
	Yes	No	Yes	No	
Q17: Information about the cancer diagnosis?	6 (5.3%)	108 (94.7%)	4 (3.5%)	110 (96.5%)	0.75*
Q18: Information about the different types of treatment, including side effects? (e.g. surgery, chemotherapy, radiotherapy)	2 (1.8%)	109 (98.2%)	1 (0.9%)	110 (99.1%)	1.0*
Q19: Information about whether your children or other members of the family are at risk of getting endometrial (womb) cancer?	16 (14.3%)	96 (85.7%)	31 (27.7%)	81 (72.3%)	0.10
Q20: Information about how the treatment may have affected your feelings about your body, your sexual attractiveness and sexual function	7 (6.3%)	105 (93.8%)	12 (10.8%)	99 (89.2%)	0.80
Q21: Information about caring for yourself? (e.g. diet, support groups, finances, psychological support)	10 (8.8%)	103 (91.2%)	14 (12.4%)	99 (87.6%)	0.12
Q22: Have you had any concerns about how your family are coping with your diagnosis	4 (3.5%)	110 (96.5%)	5 (4.5%)	106 (95.5%)	0.30
Q23: Do you need information about anything else not mentioned in questions 17-22?	1 (0.9%)	111 (99.1%)	2 (1.8%)	111 (98.2%)	1.0*

